Balyasny Asset Management L.P. Has $1.35 Million Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Balyasny Asset Management L.P. lessened its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 96.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,274 shares of the biotechnology company's stock after selling 64,384 shares during the quarter. Balyasny Asset Management L.P.'s holdings in Axon Enterprise were worth $1,351,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Artemis Investment Management LLP grew its holdings in Axon Enterprise by 21.4% in the fourth quarter. Artemis Investment Management LLP now owns 95,113 shares of the biotechnology company's stock valued at $56,528,000 after purchasing an additional 16,792 shares during the last quarter. Decker Retirement Planning Inc. acquired a new stake in Axon Enterprise in the 4th quarter worth about $2,985,000. MRA Advisory Group lifted its stake in shares of Axon Enterprise by 64.4% in the 4th quarter. MRA Advisory Group now owns 3,205 shares of the biotechnology company's stock valued at $1,905,000 after purchasing an additional 1,255 shares in the last quarter. Perigon Wealth Management LLC acquired a new position in shares of Axon Enterprise in the 4th quarter valued at about $488,000. Finally, Czech National Bank lifted its stake in shares of Axon Enterprise by 7.4% in the 4th quarter. Czech National Bank now owns 15,707 shares of the biotechnology company's stock valued at $9,335,000 after purchasing an additional 1,082 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on AXON shares. Northcoast Research downgraded Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. Needham & Company LLC boosted their price target on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. The Goldman Sachs Group boosted their price target on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday. Craig Hallum downgraded Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Finally, JMP Securities reaffirmed an "outperform" rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of "Moderate Buy" and a consensus price target of $652.73.

Axon Enterprise Stock Up 0.7%

NASDAQ:AXON traded up $4.79 during trading hours on Friday, hitting $733.18. 419,101 shares of the company's stock traded hands, compared to its average volume of 759,084. The firm has a market cap of $57.08 billion, a P/E ratio of 189.45, a P/E/G ratio of 5.17 and a beta of 1.24. Axon Enterprise, Inc. has a twelve month low of $273.52 and a twelve month high of $735.68. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The stock's fifty day moving average price is $584.61 and its two-hundred day moving average price is $593.44.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The firm had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the previous year, the company posted $1.15 earnings per share. The business's quarterly revenue was up 31.3% compared to the same quarter last year. On average, research analysts expect that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $540.99, for a total value of $5,409,900.00. Following the completion of the transaction, the chief executive officer now owns 3,063,982 shares of the company's stock, valued at $1,657,583,622.18. This represents a 0.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Matthew R. Mcbrady sold 400 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $718.40, for a total value of $287,360.00. Following the completion of the transaction, the director now directly owns 3,492 shares of the company's stock, valued at approximately $2,508,652.80. The trade was a 10.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,764 shares of company stock worth $14,856,635 over the last 90 days. 4.40% of the stock is currently owned by corporate insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.